Chemokine Receptor Antagonists in Combination with Morphine as a Novel Strategy for Opioid Dose Reduction in Pain...

Area of Science:

• Pharmacology
• Immunology
• Pain Management

Background:

• Opioids are commonly prescribed for pain but often have limited efficacy.
• Chemokines, released during inflammation, can interfere with opioid analgesia through heterologous desensitization.
• Targeting chemokine receptors presents a potential strategy to modulate opioid effectiveness.

Purpose of the Study:

• To investigate if chemokine receptor antagonists (CRAs) can enhance morphine potency in preclinical pain models.
• To test the hypothesis that co-administration of CRAs with morphine improves analgesia.

Main Methods:

• Utilized three rodent pain assays: incisional pain in rats, cold-water tail flick test in rats, and formalin test in mice.
• Employed FDA-approved CRAs: maraviroc (targeting CCR5/CCL5) and AMD3100 (targeting CXCR4/CXCL4).
• Assessed the effects of CRAs, alone and in combination with morphine, on pain responses.

Main Results:

• Co-administration of CRAs with morphine significantly enhanced morphine potency, shifting dose-response curves leftward by up to 3.3-fold in incisional pain.
• Significant increases in morphine's antinociceptive effects were observed when combined with CRAs in the cold-water tail flick and formalin tests.
• Both single and dual CRA combinations potentiated morphine's analgesic effects.

Conclusions:

• The findings support the development of an opioid-sparing approach for pain management.
• Combining CRAs with reduced doses of morphine shows promise for improving pain relief efficacy.
• This strategy could lead to more effective pain treatments with potentially lower opioid reliance.